Novel Drug Shows Benefits in Rare C3G and Primary IC-MPGN

Pegcetacoplan substantially reduced proteinuria in these potentially debilitating rare kidney diseases in a new phase 3 study.
Medscape Medical News

source https://www.medscape.com/viewarticle/novel-drug-targeting-c3-c3b-shows-benefits-rare-c3-2024a1000jpt?src=rss